Robeco Institutional Asset Management Boosts Regeneron Pharmaceuticals Stake

Investment firm increases holdings in biotech company by over 116%

Apr. 12, 2026 at 10:39am

Got story updates? Submit your updates here. ›

An extreme close-up of the complex machinery and components inside a pharmaceutical manufacturing facility, representing the technical sophistication and industrial scale behind Regeneron's drug development.Robeco's increased investment in Regeneron reflects the biotech firm's industrial-scale capabilities and innovative drug pipeline.Tarrytown Today

Robeco Institutional Asset Management B.V. has significantly increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), adding 140,966 additional shares during the fourth quarter. This represents a 116.6% increase in the firm's holdings, bringing its total stake in the biopharmaceutical company to 261,850 shares worth over $202 million.

Why it matters

The substantial increase in Robeco's Regeneron position suggests the investment firm sees significant upside potential in the biotech company's stock. Regeneron is a leading developer of innovative medicines, and its portfolio of approved drugs and pipeline of promising candidates make it an attractive long-term investment.

The details

According to a recent 13F filing, Robeco Institutional Asset Management B.V. purchased an additional 140,966 shares of Regeneron Pharmaceuticals during the fourth quarter of 2025. This increased the firm's total position to 261,850 shares, representing about 0.25% of the company's outstanding stock. Robeco cited Regeneron's strong product portfolio and development pipeline as key factors behind the investment decision.

  • Robeco Institutional Asset Management B.V. made the share purchases during the fourth quarter of 2025.

The players

Robeco Institutional Asset Management B.V.

A global asset management firm that oversees over $200 billion in client assets.

Regeneron Pharmaceuticals, Inc.

A leading biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

Robeco's substantial increase in its Regeneron position highlights the investment firm's confidence in the biotech company's growth prospects. As Regeneron continues to advance its pipeline and expand its commercial product offerings, it remains an appealing investment for institutional investors seeking exposure to the innovative pharmaceutical sector.